Quantitative Evaluation of mMate1 Function Based on Minimally Invasive Measurement of Tissue Concentration Using PET with [11C]Metformin in Mouse

PurposeTo evaluate the function of multidrug and toxin extrusion proteins (MATEs) using 11C-labeled metformin ([11C]metformin) by positron emission tomography (PET).MethodsPET was performed by intravenous bolus injection of [11C]metformin. Pyrimethamine at 0.5 and 5 mg/kg was intravenously administered to mice 30 min prior to the scan. Integration plot analysis was conducted for calculating liver (CLuptake,liver), kidney (CLuptake,kidney) tissue uptake, intrinsic biliary (CLint,bile) and urinary (CLint,urine) excretion clearances of [11C]metformin.ResultsVisualization by PET showed that pyrimethamine increased concentrations of [11C]metformin in the liver and kidneys, and decreased the concentrations in the urinary bladder without changing the blood profiles. Pyrimethamine had no effect on the CLuptake,liver and CLuptake,kidney, which were similar to the blood-flow rate. CLint,bile with regard to the liver concentration was unable to be determined, but administration of 0.5 and 5 mg/kg of pyrimethamine increased the liver-to-blood ratio to 1.6 and 2.3-fold, respectively, indicating that pyrimethamine inhibited the efflux of [11C]metformin from the liver. CLint,urine with regard to the corticomedullary region concentrations was decreased 37 and 68% of the control by administration of 0.5 and 5 mg/kg of pyrimethamine, respectively (P < 0.05).ConclusionsTissue concentration based investigations using [11C]metformin by PET enables the functional analysis of MATEs in the liver and kidneys.

[1]  K. Giacomini,et al.  Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics , 2008, Clinical pharmacology and therapeutics.

[2]  H. Kusuhara,et al.  Imaging in the Study of Membrane Transporters , 2013, Clinical pharmacology and therapeutics.

[3]  Kazuya Maeda,et al.  PET Imaging–Based Evaluation of Hepatobiliary Transport in Humans with (15R)-11C-TIC-Me , 2012, The Journal of Nuclear Medicine.

[4]  Osamu Ogawa,et al.  Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. , 2007, Biochemical pharmacology.

[5]  Yuichi Sugiyama,et al.  Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  Yuichi Sugiyama,et al.  Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin , 2002, Journal of Pharmacology and Experimental Therapeutics.

[7]  A. Yonezawa,et al.  Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics , 2011, British journal of pharmacology.

[8]  Hiroshi Omote,et al.  A human transporter protein that mediates the final excretion step for toxic organic cations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Matthijs L. Becker,et al.  Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study , 2009, Diabetes.

[10]  Yasuyoshi Watanabe,et al.  The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo. , 2013, Bioorganic & medicinal chemistry.

[11]  Geraldine Rauch,et al.  Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. , 2013, British journal of clinical pharmacology.

[12]  Kazuya Maeda,et al.  Positron Emission Tomography Studies Using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin Methyl Ester for the Evaluation of Hepatobiliary Transport , 2010, Journal of Pharmacology and Experimental Therapeutics.

[13]  C. McCarty,et al.  The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin , 2013, Clinical pharmacology and therapeutics.

[14]  O. Ogawa,et al.  Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. , 2006, Journal of the American Society of Nephrology : JASN.

[15]  Y Kumagai,et al.  Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects , 2011, Clinical pharmacology and therapeutics.

[16]  Yasuyoshi Watanabe,et al.  Evaluation of Oatp and Mrp2 Activities in Hepatobiliary Excretion Using Newly Developed Positron Emission Tomography Tracer [11C]Dehydropravastatin in Rats , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[17]  A. Yonezawa,et al.  Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. , 2010, Biochemical pharmacology.

[18]  A. Somogyi,et al.  Reduction of metformin renal tubular secretion by cimetidine in man. , 1987, British journal of clinical pharmacology.

[19]  D. Tweedie,et al.  Highlights from the International Transporter Consortium Second Workshop , 2012, Clinical pharmacology and therapeutics.

[20]  T. Iwatsubo,et al.  Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  Yasuyoshi Watanabe,et al.  The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [¹¹C]telmisartan. , 2011, Molecular pharmaceutics.

[22]  Yasuyoshi Watanabe,et al.  Synthesis of [(11)C]dehydropravastatin, a PET probe potentially useful for studying OATP1B1 and MRP2 transporters in the liver. , 2012, Bioorganic & medicinal chemistry.

[23]  T. Mizuno,et al.  Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin , 2009, Molecular Pharmacology.

[24]  C. Yokoyama,et al.  Developmental Changes in P-Glycoprotein Function in the Blood–Brain Barrier of Nonhuman Primates: PET Study with R-11C-Verapamil and 11C-Oseltamivir , 2011, The Journal of Nuclear Medicine.

[25]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[26]  Yasuyoshi Watanabe,et al.  Evaluation of Breast Cancer Resistance Protein Function in Hepatobiliary and Renal Excretion Using PET with 11C-SC-62807 , 2013, The Journal of Nuclear Medicine.

[27]  Satohiro Masuda,et al.  Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells , 2009, Journal of Pharmacology and Experimental Therapeutics.

[28]  H. Beck-Nielsen,et al.  A gene–gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin , 2013, Pharmacogenetics and genomics.

[29]  Brian Tomlinson,et al.  OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine , 2008, Pharmacogenetics and genomics.

[30]  H. Kusuhara,et al.  Competitive Inhibition of the Luminal Efflux by Multidrug and Toxin Extrusions, but Not Basolateral Uptake by Organic Cation Transporter 2, Is the Likely Mechanism Underlying the Pharmacokinetic Drug-Drug Interactions Caused by Cimetidine in the Kidney , 2012, Journal of Pharmacology and Experimental Therapeutics.

[31]  Y. Moriyama,et al.  Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  L Zhang,et al.  Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium , 2013, Clinical pharmacology and therapeutics.

[33]  H. Kusuhara,et al.  Potent and Specific Inhibition of mMate1-Mediated Efflux of Type I Organic Cations in the Liver and Kidney by Pyrimethamine , 2010, Journal of Pharmacology and Experimental Therapeutics.

[34]  K. Inui,et al.  Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). , 2008, Biochemical pharmacology.